骨成型蛋白2(BMP2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Bone Morphogenetic Protein 2 (BMP2)
BMP2A; BMP-2A; Hemochromatosis Modifier
- 編號(hào)SEA013Po
- 物種Sus scrofa; Porcine (Pig，豬)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍31.25-2000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于13.1pg/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids.
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 3175¥ 4536¥ 20412¥ 38556¥ 317520
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)骨成型蛋白2(BMP2)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的骨成型蛋白2(BMP2)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 91-104 | 96 |
| EDTA plasma(n=5) | 93-101 | 96 |
| heparin plasma(n=5) | 91-101 | 96 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的骨成型蛋白2(BMP2)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中骨成型蛋白2(BMP2)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-98% | 90-103% | 96-103% | 90-105% |
| EDTA plasma(n=5) | 89-97% | 79-90% | 83-97% | 88-97% |
| heparin plasma(n=5) | 80-90% | 84-93% | 96-105% | 99-105% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將骨成型蛋白2(BMP2)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的骨成型蛋白2(BMP2)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的骨成型蛋白2(BMP2)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的骨成型蛋白2(BMP2)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Sus scrofa; Porcine (Pig，豬) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA013Po01 | 骨成型蛋白2(BMP2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA013Po02 | 骨成型蛋白2(BMP2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA013Po01 | 骨成型蛋白2(BMP2)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA013Po02 | 骨成型蛋白2(BMP2)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA013Po71 | 骨成型蛋白2(BMP2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA013Po | 骨成型蛋白2(BMP2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA013Po | 骨成型蛋白2(BMP2)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA013Po | 骨成型蛋白2(BMP2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Journal of Applied Toxicology | Chronic exposure to low concentrations of strontium 90 affects bone physiology but not the hematopoietic system in mice[Wiley: Source] |
| PLoS ONE | A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches[Plosone: Source] |
| Medical Journal of Chinese People's Liberation Army | Effect of transplantation of BMP-2-induced bone marrow mesenchymal stem cells on myocardial infarction of rats after reperfusion[Source] |
| PLOS ONE | PDGF-AA promotes osteogenic differentiation and migration of mesenchymal stem cell by down-regulating PDGFRα and derepressing BMP-Smad1/5/8 signaling[Pubmed:25470749] |
| Eur J Pharmacol | Negative effect of serotonin–norepinephrine reuptake inhibitor therapy on rat bone tissue after orchidectomy[PubMed: 25934570] |
| Pharmacology | Effect of Mirtazapine on Rat Bone Tissue after Orchidectomy[PubMed: 25871861] |
| Journal of Cellular Biochemistry | Titanium with Nanotopography Induces Osteoblast Differentiation by Regulating Endogenous Bone Morphogenetic Protein Expression and Signaling Pathway[PubMed: 26681207] |
| International Journal of Nanomedicine | Sustained dual release of placental growth factor-2 and bone morphogenic protein-2 from heparin-based nanocomplexes for direct osteogenesis[Pubmed:27042064] |
| Research report | EFFECTS OF FLUORIDE ON THE EXPRESSION OF BMP-2 AND SMAD1 IN RAT OSTEOBLASTS IN VITRO[files:p013-022] |
| Gene? | Unveiling the interactions among BMPR-2, ALK-1 and 5-HTT genes in the pathophysiology of HAPE[Pubmed:27196063] |
| Journal of Materials Chemistry B | Extracellular Matrix Powder from Cultured Cartilage-Like Tissue as Cell Carriers for Cartilage Repair[DOI:10.1039/C7TB00640C] |
| Scientific Reports | 3D- Printed Poly(ε-caprolactone) Scaffold Integrated with Cell-laden Chitosan Hydrogels for Bone Tissue Engineering.[pubmed:29042614] |
| Journal of Applied Biomaterials & Functional Materials | Demineralized dentin and enamel matrices as suitable substrates for bone regeneration[pubmed:28731486] |
| Journal of?Clinical?Periodontology? | Peroxisome proliferator‐activated receptor γ plays dual roles on experimental periodontitis in rats[Pubmed:29574908] |
| Pharmacology | Effects of Amlodipine on Bone Metabolism in Orchidectomised Spontaneously Hypertensive Rats[Pubmed:29898457] |
| Journal of?Applied?Biomaterials?&?Functional?Materials | BMP-2 and type I collagen preservation in human deciduous teeth after demineralization[Pubmed:30045659] |
| Applied Surface Science | Enhanced osteogenic differentiation of MC3T3-E1 on rhBMP-2 immobilized titanium surface through polymer-mediated electrostatic interaction[] |
| Materials Science and Engineering: C | Injectable hydrogels from enzyme-catalyzed crosslinking as BMSCs-laden scaffold for bone repair and regeneration[] |
| Biomaterials Science | Development of CaCO 3 microsphere-based composite hydrogel for dual delivery of growth factor and Ca to enhance bone regeneration[] |
| ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY | The dose-time effects of fluoride on the expression and DNA methylation level of the promoter region of BMP-2 and BMP-7 in rats[Pubmed: 32004919] |
| Journal of Industrial and Engineering Chemistry | Biofabrication and application of decellularized bone extracellular matrix for effective bone regeneration[] |
| BMC Musculoskeletal Disorders | Synergistic Effect of Platelet-rich Fibrin Releasate and Bone Marrow Stem Cells in Preventing Bone Loss in Ovariectomized Mouse[] |
| Bioact Mater | New design to remove leukocytes from platelet-rich plasma (PRP) based on cell dimension rather than density[33842739] |
| Tissue Eng Regen Med | Osteogenic and Angiogenic Potency of VEGF165-Transfected Canine Bone Marrow Mesenchymal Cells Combined with Coral Hydroxyapatite in Vitro[34302695] |
| Toxicon | The WNT/β-catenin signalling pathway induces chondrocyte apoptosis in the cartilage injury caused by T-2 toxin in rats[34742779] |
| ACS Biomater Sci Eng | Polydopamine-Coated Poly(l-lactide) Nanofibers with Controlled Release of VEGF and BMP-2 as a Regenerative Periosteum[34472855] |
| Phytomedicine | Efficacy of Total flavonoids of Rhizoma drynariae on the Blood Vessels and the Growth Quality of Bone Graft in the Induced Membrane[Pubmed:35278899] |
